Genomics services company Caprion-HistoGeneX said on Thursday that it will expand its global capabilities to address the emerging needs for therapeutic and prophylactic solutions aimed at developing vaccines and other therapies for infectious diseases including COVID-19 under a new strategic partnership with Viroclinics-DDL.

The combined expertise of both the companies allows for a seamless, integrated service experience for customers worldwide, with a broad service offering covering all stages of vaccine and antiviral development, ranging from preclinical and in-vitro research models to the deployment of custom-developed and off-the-shelf functional assays for monitoring vaccine efficacy.

Based on the specialized platforms of viral neutralization, flow cytometry, ELISpot and immuno-assays, the partnership will provide access to an extended global network of clinical sample processing facilities across North America, South America, Europe, Africa and Asia, along with operational and logistical services including sample management and sampling kits.